A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 27 150 KRW 2.84% Market Closed
Market Cap: 1.3T KRW
Have any thoughts about
ABL Bio Inc?
Write Note

ABL Bio Inc
Accumulated Depreciation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ABL Bio Inc
Accumulated Depreciation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accumulated Depreciation CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Accumulated Depreciation
-â‚©602.7B
CAGR 3-Years
-10%
CAGR 5-Years
-11%
CAGR 10-Years
-15%
SK Bioscience Co Ltd
KRX:302440
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Accumulated Depreciation
-â‚©56.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Accumulated Depreciation
-â‚©40B
CAGR 3-Years
-26%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Accumulated Depreciation
-â‚©9.5B
CAGR 3-Years
-13%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
No Stocks Found

ABL Bio Inc
Glance View

Market Cap
1.3T KRW
Industry
Biotechnology

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
8 401.38 KRW
Overvaluation 69%
Intrinsic Value
Price
A

See Also

Back to Top